Provided by Tiger Fintech (Singapore) Pte. Ltd.

CARSGEN-B

23.100
-0.250-1.07%
Volume:1.28M
Turnover:29.58M
Market Cap:13.31B
PE:-14.62
High:24.050
Open:24.000
Low:22.600
Close:23.350
Loading ...

CARsgen Therapeutics to Trim Stake in Biotech Arm After Third-Party Investment

MT Newswires Live
·
27 Feb

BRIEF-Carsgen Therapeutics Says Introduction Of Zhuhai Sb Xinchuang In China

Reuters
·
26 Feb

CARsgen Therapeutics - Introduction of Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China

THOMSON REUTERS
·
26 Feb

CARsgen Therapeutics - Investment Fund to Subscribe for Additional Registered Capital of Ucarsgen Biotech for RMB80 Mln

THOMSON REUTERS
·
26 Feb

CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China

THOMSON REUTERS
·
25 Feb

CARsgen Therapeutics Holdings Limited's (HKG:2171) stock price dropped 6.5% last week; retail investors would not be happy

Simply Wall St.
·
28 Jan

CARsgen's Allogeneic Cd19/Cd20 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial

THOMSON REUTERS
·
13 Jan

CARsgen Announces the Initiation of an Investigator-Initiated Trial for an Allogeneic Cd19/Cd20 CAR-T Therapy

THOMSON REUTERS
·
31 Dec 2024

Stock Track | CARsgen-B Soars 5.98% on Positive Topline Results from Phase II CAR-T Trial

Stock Track
·
31 Dec 2024

BRIEF-CARsgen Announces Topline Results From China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T

Reuters
·
30 Dec 2024

CARsgen Therapeutics Holdings Ltd: Anticipate Submitting an Nda to Nmpa in First Half of 2025

THOMSON REUTERS
·
30 Dec 2024

CARsgen Announces Positive Topline Results From China GC/Gej Pivotal Phase Ii Clinical Trial of Claudin18.2 CAR-T (Satri-Cel)

THOMSON REUTERS
·
30 Dec 2024

CARsgen Therapeutics Holdings Ltd - Study Meets Primary Endpoint of Improved Pfs

THOMSON REUTERS
·
30 Dec 2024

CARsgen Therapeutics Records Positive Phase 2 Clinical Results for Anti-Cancer Drug

MT Newswires Live
·
30 Dec 2024